- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.11. | Artiva BioTherapeutics GAAP EPS of -$0.88 | 3 | Seeking Alpha | ||
| 12.11. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease | 178 | GlobeNewswire (Europe) | 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were... ► Artikel lesen | |
| 12.11. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 103 | GlobeNewswire (Europe) | Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®... ► Artikel lesen | |
| 12.11. | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.10. | Cantor Fitzgerald reiterates Overweight rating on Artiva Biotherapeutics stock | 18 | Investing.com | ||
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.10. | Rheumatoide Arthritis: Artiva erhält FDA Fast-Track-Status für Zelltherapie AlloNK | 4 | Investing.com Deutsch | ||
| 16.10. | Artiva's AlloNK receives FDA Fast Track status for rheumatoid arthritis | 3 | Investing.com | ||
| 16.10. | Artiva Biotherapeutics stock soars after FDA Fast Track designation | 1 | Investing.com | ||
| 16.10. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | 320 | GlobeNewswire (Europe) | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen | |
| 07.08. | Artiva Biotherapeutics GAAP EPS of -$0.87 misses by $0.06 | 2 | Seeking Alpha | ||
| 06.08. | Artiva Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.08. | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT ... | 152 | GlobeNewswire (Europe) | 64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL... ► Artikel lesen | |
| 08.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights | 326 | GlobeNewswire (Europe) | IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis ... ► Artikel lesen | |
| 08.04. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer | 803 | GlobeNewswire (Europe) | SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies... ► Artikel lesen | |
| 24.03. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights | 222 | GlobeNewswire (Europe) | Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,95 | -1,05 % | BioNTech: Starke Studiennews - Aktie zieht an | Die Aktie von BioNTech kann zum Wochenstart deutlich zulegen. Gute News vom Wochenende zum Produktkandidaten BNT316 bei Lungenkrebs unterstützen die Aktie. Für einen charttechnischen Befreiungsschlag... ► Artikel lesen | |
| CUREVAC | 4,262 | -1,02 % | EILMELDUNG: Curevac-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| AMGEN | 276,75 | +2,22 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,608 | +0,12 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 148,65 | +0,20 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| MAINZ BIOMED | 1,030 | -1,90 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,210 | -1,12 % | Viking Therapeutics-Aktie: Was kommt 2026? | Kurz vor Jahresende nehmen wir die Aktie von Viking Therapeutics noch einmal unter die Lupe, denn das Unternehmen steht vor einem entscheidenden Jahr für seine Adipositas-Pipeline. Zwar sind keine Zulassungsentscheidungen... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,692 | +0,05 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 59,00 | -2,48 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| BIOCRYST PHARMACEUTICALS | 6,384 | -1,08 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,470 | +1,31 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,275 | -0,38 % | Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing | ||
| EXELIXIS | 35,420 | +1,75 % | Exelixis stock holds steady as Stifel maintains $43 price target | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,748 | -3,46 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,893 | -0,45 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen |
Das Unternehmen ARTIVA BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,300 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.